唑來膦酸治療老年骨質(zhì)疏松癥的效果及對(duì)骨痛緩解的影響

李堃宜

[摘要]目的 探討對(duì)老年骨質(zhì)疏松癥患者實(shí)施唑來膦酸治療的效果及對(duì)骨痛緩解的影響。方法 選取2015年3月～2017年4月我院收治的52例老年骨質(zhì)疏松癥患者作為研究對(duì)象，根據(jù)治療方式的不同分為對(duì)照組（24例）和實(shí)驗(yàn)組（28例），對(duì)照組給予碳酸鈣D3咀嚼片+阿法骨化醇膠丸治療，實(shí)驗(yàn)組給予碳酸鈣D3咀嚼片+阿法骨化醇膠丸+唑來膦酸治療。比較兩組患者的疼痛評(píng)分、血鈣、血膦、堿性磷酸酶（ALP）水平及不良反應(yīng)總發(fā)生率。結(jié)果 實(shí)驗(yàn)組患者治療3、6個(gè)月后的疼痛評(píng)分低于對(duì)照組，差異均有統(tǒng)計(jì)學(xué)意義（P<0.05）;實(shí)驗(yàn)組患者治療6個(gè)月后ALP水平為（98.27±15.36）IU/L，低于對(duì)照組的（142.27±19.36）IU/L，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）;兩組患者治療6個(gè)月后的血鈣、血膦水平比較，差異無統(tǒng)計(jì)學(xué)意義（P>0.05）;兩組患者的不良反應(yīng)總發(fā)生率比較，差異無統(tǒng)計(jì)學(xué)意義（P>0.05）。結(jié)論 對(duì)老年骨質(zhì)疏松癥患者實(shí)施唑來膦酸治療具有較好的效果，可顯著緩解骨痛，安全性較高。

[關(guān)鍵詞]老年;骨質(zhì)疏松癥;唑來膦酸;堿性磷酸酶;疼痛評(píng)分;血鈣;血膦;不良反應(yīng)

[中圖分類號(hào)] R683? ? ? ? ? [文獻(xiàn)標(biāo)識(shí)碼] A? ? ? ? ? [文章編號(hào)] 1674-4721（2019）2（a）-0124-03

[Abstract] Objective To explore the effect of Zoledronic Acid treatment on elderly patients with osteoporosis and its effect on bone pain relief. Methods Fifty-two elderly patients with osteoporosis admitted to our hospital from March 2015 to April 2017 were selected as the research objects， they were divided into control group （24 cases） and experimental group （28 cases） according to different treatment methods， the control group was treated with Calcium Cartonate and Vitamin D3 Chewabie Tablets and Alfacalciferol soft Capsules， while the experimental group was treated with Calcium Carttonate and Vitamin D3 Chewabie Tablets， Alfacalciferol soft Capsules and Zoledronic Acid. Pain score， serum calcium， phosphorus， alkaline phosphatase （ALP） levels and total incidence of adverse reactions were compared between the two groups. Results The pain score of the experimental group after 3 and 6 months of treatment was lower than that of the control group， the differences were statistically significant（P<0.05）. After 6 months of treatment， the ALP level in the experimental group was （98.27±15.36） IU/L， which was lower than （142.27±19.36） IU/L in the control group ， the difference was statistically significant （P<0.05）. There were no significant differences in serum calcium and phosphorus levels between the two groups after 6 months of treatment （P>0.05）. There was no significant difference in the total incidence of adverse reactions between the two groups （P>0.05）. Conclusion Zoledronic Acid has a good effect on elderly patients with osteoporosis. It can significantly alleviate bone pain and has high safety.

[Key words] Senile; Osteoporosis; Zolephosphoric Acid; Alkaline Phosphatase; Pain score; Blood calcium; Blood phosphorus; Adverse reaction

骨質(zhì)疏松癥屬于臨床骨科的常見病，主要以低骨量及骨組織微結(jié)構(gòu)破壞為特點(diǎn)，導(dǎo)致骨質(zhì)脆性增加的一種臨床綜合征，以疼痛、身長(zhǎng)縮短、駝背、骨折、呼吸功能下降等為主要臨床癥狀[1-2]，該疾病以老年人群為主，隨著人口老齡化問題的加劇，骨質(zhì)疏松癥的患病率呈現(xiàn)顯著上升的趨勢(shì)，在一定程度上威脅了老年群體的生存質(zhì)量，同時(shí)較多研究證實(shí)，若不及時(shí)對(duì)患者實(shí)施有效醫(yī)治，嚴(yán)重者可引發(fā)骨折，極大程度威脅了患者的身體健康[3]。目前，臨床治療骨質(zhì)疏松癥以保守療法為主，其中藥物療法是常用手段，我院對(duì)老年骨質(zhì)疏松癥患者分別實(shí)施碳酸鈣D3咀嚼片+阿法骨化醇膠丸和碳酸鈣D3咀嚼片+阿法骨化醇膠丸+唑來膦酸治療，探討唑來膦酸的治療效果，現(xiàn)報(bào)道如下。